| UK cost agency doesn't favour UCB arthritis drug |
| A National Institute for Health and Clinical Excellence (NICE) committee said there were limitations in submitted economic models for the drug, which led to a "high degree of uncertainty". |
More
-
ENERGY XXI GOM, LLC (form EFFECT)
ENERGY XXI GOM, LLC Files SEC form EFFECT, Effectiveness Order
-
ACCENTIA BIOPHARMACEUTICALS INC (form EFFECT)
ACCENTIA BIOPHARMACEUTICALS INC Files SEC form EFFECT, Effectiveness Order